Assessment of the impact lipoprotein lipase gene variation on the response to rosuvastatin therapy in coronary artery disease patients in Al Najaf Governorate
Keywords:
coronary artery, cholesterol, Al-Najaf governorateAbstract
Background: One of the first line commonly used oral HMG reductase inhibitor is rosuvastatin. The variants of pharmacokinetic genes have not demonstrated a consistent and significant influence on rosuvastatin response in patients with coronary artery, in candidate gene studies. In addition, only few genome-wide signals associated with rosuvastatin pharmacological response have been detected to the present time.
Aim of the study: To study the impact of Hind iii gene single nucleotides polymorphisms (rs 320) on rosuvastatin response in coronary artery disease patients in Al-Najaf governorate.
Patients and methods: The current prospective cohort study included 51 patients with coronary artery disease. The work with the study is dated back to December 2021 to September 2022. The study was carried out at internal medicine department in Al- Sader Teaching Hospital-Najaf- Iraq. The enrolled patients with coronary artery disease have been diagnosed by a cardiologist. The age ranged from 23 to 65 years. The first blood sample was taken at time zero (time of diagnosis without treatment) and the second blood sample was taken after 8 weeks (after starting treatment) for each patient.
Results: The mean serum of triglyceride level, total cholesterol, VLDL-C, LDL-C, interleukin 6 level and mean body mass index (BMI) significantly reduced (p<0.0001). while serum of HDL-C and lipoprotein lipase level significantly increased (p< 0.0001) after treatment with rosuvastatin. The LPL rs320 genotyping was: wild allele (TT), heterozygote variant (TG) and homozygote variant (GG).
Conclusions: In our research heterozygous variant most distributed then homozygous normal and the less distributed was homozygous variant. Rosuvastatin has been shown to be effective in improvement of serum lipid profile, lipoprotein lipase level and interleukin 6 level.
References
Adams SP, Sekhon SS, Wright JM. Rosuvastatin for lowering lipids. Cochrane Database of Systematic Reviews, 2014, 11.
Ades PA, Savage PD. Obesity in coronary heart disease: An unaddressed behavioral risk factor. Preventive Medicine. 2017;104:117-119.
Artiss JD, Zak B. Measurement of cholesterol concentration. Handbook of Lipoprotein Testing. AACC Press, New York, 2000, 189-205.
Brown JC, Gerhardt TE, Kwon E. Risk factors for coronary artery disease, 2020.
Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low‐density lipoprotein cholesterol in a usual care setting. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2006;26(4):469-478.
Campbell SC, Moffatt RJ, Stamford BA. Smoking and smoking cessation-the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis. 2008;201(2):225-235.
Cho YR, Ann SH, Won KB, Park GM, Kim YG, Yang DH, et al. Association between insulin resistance, hyperglycemia, and coronary artery disease according to the presence of diabetes. Scientific Reports. 2019;9(1):1-7.
Hasnat MA, Niloy FR, Ashik AI, Hasan M, Dev PC, Panna SS, et al. Prevalence of hyperlipidemia in controlled and uncontrolled type-2 diabetic patients. System. 2019;22:23.
Heinrich J, Schulte H, Schönfeld R, Köhler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thrombosis and Haemostasis. 1995;73(03):374-379.
Hoff JA, Quinn L, Sevrukov A, Lipton RB, Daviglus M, Garside DB, et al. The prevalence of coronary arterycalcium among diabetic individuals without known coronary artery disease. Journal of the American College of Cardiology. 2003;41(6):1008-1012.
Hosseini K, Mortazavi SH, Sadeghian S, Ayati A, Nalini M, Aminorroaya A, et al. Prevalence and trends of coronary artery disease risk factors and their effect on age of diagnosis in patients with established coronary artery disease: Tehran Heart Center (2005–2015). BMC Cardiovascular Disorders. 2021;21:1-11.
Kanna DEN, Packirisamy S. Current updates on angina pectoris-A deadly oxygen thirst of the heart. Current Research in Life Sciences, 2023, 33.
Kannel WB. Hypertension: reflections on risks and prognostication. Medical Clinics of North America. 2009;93(3):541-558.
Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery. 1982;11(3):337-343.
Katta N, Loethen T, Lavie CJ, Alpert MA. Obesity and coronary heart disease: epidemiology, pathology, and coronary artery imaging. Current Problems in Cardiology. 2021;46(3):100655.
Kumar B, Shah MAA, Kumar R, Kumar J, Memon A. Comparison of atorvastatin and rosuvastatin in reduction of inflammatory biomarkers in patients with acute coronary syndrome. Cureus, 2019, 11(6).
Lloyd-Jones DM, Leip EP, Larson MG, D’agostino RB, Beiser A, Wilson PWF, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791-798.
Mansour HM, Obaid HAA, Bursh WA, Elessi K. Comparison between 20 mg versus 40 mg dose of atorvastatin among dyslipidemic patients associated with diabetes or coronary artery disease: a randomized clinical trial. Medicine. 2017;6(2):347-350.
McCance KL, Huether SE. Pathophysiology-E-book: the biologic basis for disease in adults and children. Elsevier Health Sciences, 2018.
McGarry M, Shenvi CL. Identification of acute coronary syndrome in the elderly. Emergency Medicine Clinics. 2021;39(2):339-346.
Misra A. Ethnic-specific criteria for classification of body mass index: a perspective for Asian Indians and American Diabetes Association position statement. Diabetes Technology & Therapeutics. 2015;17(9):667–671.
Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Canadian Journal of Cardiology. 2021;37(8):1129-1150.
Pepine CJ. Systemic hypertension and coronary artery disease. The American Journal of Cardiology. 1998;82(3):21-24.
Qin R, Chen T, Lou Q, Yu D. Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies. International Journal of Cardiology. 2013;167(2):342-350.
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. The Lancet. 2012;380(9841):565-571.
Rodgers JL, Jones J, Bolleddu SI, Vanthenapalli S, Rodgers LE, Shah K, et al. Cardiovascular risks associated with gender and aging. Journal of Cardiovascular Development and Disease. 2019;6(2):19.
Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Annals of Translational Medicine, 2016, 4(13).
Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. European Heart Journal. 2021;42(3):243-252.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama. 2016;315(8):801-810.
Weir CB, Jan A. BMI classification percentile and cut off points, 2019.
Williams B. Recent hypertension trials: implications and controversies. Journal of the American College of Cardiology. 2005;45(6):813-827.
Winniford MD, Wheelan KR, Kremers MS, Ugolini V, Van den Berg Jr E, Niggemann EH. Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: evidence for adrenergically mediated alterations in coronary artery tone. Circulation. 1986;73(4):662-667.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Mustafa Mohammed Hussein Mahmood, Dr. Ahmed Jalal Al-Bayati, Khalida K. Al-Kelaby
This work is licensed under a Creative Commons Attribution 4.0 International License.
